Literature DB >> 15095014

Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain.

M Valenti1, D Viganò, M G Casico, T Rubino, L Steardo, D Parolaro, V Di Marzo.   

Abstract

The endogenous ligands of cannabinoid receptors, also known as endocannabinoids, have been implicated in many physiological and pathological processes of the central nervous system. Here we show that the levels of the two major endocannabinoids, anandamide and 2-arachidonoyl-glycerol (2-AG), in four areas of the rat brain, change dramatically between the light and dark phases of the day. While anandamide levels in the nucleus accumbens, pre-frontal cortex, striatum and hippocampus were significantly higher in the dark phase, the opposite was observed with 2-AG, whose levels were significantly higher during the light phase in all four regions. We found that the activity of the fatty acid amide hydrolase, which catalyzes the metabolism of anandamide, was significantly lower during the dark phase, thus providing a possible explaination for the increase in anandamide levels. However, the activities of monoacylglycerol lipase and diacylglycerol lipase, two of the possible enzymes catalyzing the degradation and biosynthesis of 2-AG, respectively, changed significantly only in the striatum. These data suggest that the levels of the two major endocannabinoids might be under the control of endogenous factors known to undergo diurnal variations, and underscore the different roles, suggested by previous studies, of anandamide and 2-AG in neurophysiological processes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15095014     DOI: 10.1007/s00018-003-3453-5

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  63 in total

1.  Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group.

Authors:  L J Steinherz; T Graham; R Hurwitz; H M Sondheimer; R G Schwartz; E M Shaffer; G Sandor; L Benson; R Williams
Journal:  Pediatrics       Date:  1992-05       Impact factor: 7.124

2.  Troponins and high-sensitivity troponins as markers of necrosis in CAD and heart failure.

Authors:  Evangelos Giannitsis; Hugo A Katus
Journal:  Herz       Date:  2009-12       Impact factor: 1.443

3.  N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?

Authors:  Maria T Sandri; Michela Salvatici; Daniela Cardinale; Laura Zorzino; Rita Passerini; Paola Lentati; Maria Leon; Maurizio Civelli; Giovanni Martinelli; Carlo M Cipolla
Journal:  Clin Chem       Date:  2005-06-02       Impact factor: 8.327

4.  Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.

Authors:  Daniela Cardinale; Alessandro Colombo; Maria T Sandri; Giuseppina Lamantia; Nicola Colombo; Maurizio Civelli; Giovanni Martinelli; Fabrizio Veglia; Cesare Fiorentini; Carlo M Cipolla
Journal:  Circulation       Date:  2006-11-13       Impact factor: 29.690

5.  The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia.

Authors:  J M Horacek; M Vasatova; M Tichy; R Pudil; L Jebavy; J Maly
Journal:  Exp Oncol       Date:  2010-07

Review 6.  Cardiac troponins--biochemical markers of cardiac toxicity after cytostatic therapy.

Authors:  D Urbanová; L Urban; A Carter; D Maasova; B Mladosievicova
Journal:  Neoplasma       Date:  2006       Impact factor: 2.575

7.  Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy.

Authors:  Márta Högye; Yvette Mándi; Miklós Csanády; Róbert Sepp; Krisztina Buzás
Journal:  Am J Cardiol       Date:  2004-07-15       Impact factor: 2.778

8.  Elevated B-type natriuretic peptide levels after anthracycline administration.

Authors:  T Suzuki; D Hayashi; T Yamazaki; T Mizuno; Y Kanda; I Komuro; M Kurabayashi; K Yamaoki; K Mitani; H Hirai; R Nagai; Y Yazaki
Journal:  Am Heart J       Date:  1998-08       Impact factor: 4.749

9.  Risk factors for doxorubicin-induced congestive heart failure.

Authors:  D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

10.  Heart-type fatty acid-binding protein predicts long-term mortality after acute coronary syndrome and identifies high-risk patients across the range of troponin values.

Authors:  Niamh Kilcullen; Karthik Viswanathan; Rajiv Das; Christine Morrell; Amanda Farrin; Julian H Barth; Alistair S Hall
Journal:  J Am Coll Cardiol       Date:  2007-11-05       Impact factor: 24.094

View more
  38 in total

1.  Circadian rhythm of circulating levels of the endocannabinoid 2-arachidonoylglycerol.

Authors:  E C Hanlon; E Tasali; R Leproult; K L Stuhr; E Doncheck; H de Wit; C J Hillard; E Van Cauter
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

2.  Differential effects of single versus repeated alcohol withdrawal on the expression of endocannabinoid system-related genes in the rat amygdala.

Authors:  Antonia Serrano; Patricia Rivera; Francisco J Pavon; Juan Decara; Juan Suárez; Fernando Rodriguez de Fonseca; Loren H Parsons
Journal:  Alcohol Clin Exp Res       Date:  2011-12-05       Impact factor: 3.455

3.  Cannabinoid-1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability.

Authors:  Cleo L Crunelle; Elsmarieke van de Giessen; Sybille Schulz; Louk J M J Vanderschuren; Kora de Bruin; Wim van den Brink; Jan Booij
Journal:  Addict Biol       Date:  2011-09-29       Impact factor: 4.280

4.  Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.

Authors:  Matthew N Hill; Erica J Carrier; Ryan J McLaughlin; Anna C Morrish; Sarah E Meier; Cecilia J Hillard; Boris B Gorzalka
Journal:  J Neurochem       Date:  2008-07-15       Impact factor: 5.372

5.  Impact of circadian rhythmicity and sleep restriction on circulating endocannabinoid (eCB) N-arachidonoylethanolamine (anandamide).

Authors:  Erin C Hanlon
Journal:  Psychoneuroendocrinology       Date:  2019-10-04       Impact factor: 4.905

6.  FAAH deficiency promotes energy storage and enhances the motivation for food.

Authors:  C Touriño; F Oveisi; J Lockney; D Piomelli; R Maldonado
Journal:  Int J Obes (Lond)       Date:  2009-12-22       Impact factor: 5.095

7.  Global deletion of MGL in mice delays lipid absorption and alters energy homeostasis and diet-induced obesity.

Authors:  John D Douglass; Yin Xiu Zhou; Amy Wu; John A Zadroga; Angela M Gajda; Atreju I Lackey; Wensheng Lang; Kristen M Chevalier; Steven W Sutton; Sui-Po Zhang; Christopher M Flores; Margery A Connelly; Judith Storch
Journal:  J Lipid Res       Date:  2015-04-04       Impact factor: 5.922

Review 8.  Endocannabinoid signalling: has it got rhythm?

Authors:  Linda K Vaughn; Gerene Denning; Kara L Stuhr; Harriet de Wit; Matthew N Hill; Cecilia J Hillard
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

9.  Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects.

Authors:  M Ellgren; A Artmann; O Tkalych; A Gupta; H S Hansen; S H Hansen; L A Devi; Y L Hurd
Journal:  Eur Neuropsychopharmacol       Date:  2008-11       Impact factor: 4.600

10.  Regulation of the hypothalamic-pituitary-adrenal axis circadian rhythm by endocannabinoids is sexually diergic.

Authors:  Helen C Atkinson; James D Leggett; Susan A Wood; Emma S Castrique; Yvonne M Kershaw; Stafford L Lightman
Journal:  Endocrinology       Date:  2010-06-09       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.